Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free RGNX Stock Alerts

REGENXBIO (RGNX) Competitors

REGENXBIO logo
$10.72 -0.34 (-3.07%)
As of 08/21/2026 04:00 PM Eastern
Compare

RGNX vs. ZLAB, NRIX, BEAM, SLS, and VRDN

Should you buy REGENXBIO stock or one of its competitors? REGENXBIO's main competitors and comparable companies include Zai Lab (ZLAB), Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), SELLAS Life Sciences Group (SLS), and Viridian Therapeutics (VRDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does REGENXBIO compare to Zai Lab?

REGENXBIO (NASDAQ:RGNX) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zai Lab has a net margin of -41.86% compared to REGENXBIO's net margin of -112.58%. Zai Lab's return on equity of -27.43% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-112.58% -220.07% -46.04%
Zai Lab -41.86%-27.43%-16.72%

REGENXBIO has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

REGENXBIO presently has a consensus price target of $23.73, suggesting a potential upside of 121.34%. Zai Lab has a consensus price target of $40.20, suggesting a potential upside of 54.56%. Given REGENXBIO's higher possible upside, equities analysts clearly believe REGENXBIO is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Zai Lab has higher revenue and earnings than REGENXBIO. Zai Lab is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M4.15-$193.88M-$3.79N/A
Zai Lab$460.16M6.43-$175.54M-$1.71N/A

In the previous week, Zai Lab had 1 more articles in the media than REGENXBIO. MarketBeat recorded 3 mentions for Zai Lab and 2 mentions for REGENXBIO. Zai Lab's average media sentiment score of 1.68 beat REGENXBIO's score of 1.36 indicating that Zai Lab is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Zai Lab beats REGENXBIO on 11 of the 17 factors compared between the two stocks.

How does REGENXBIO compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and REGENXBIO (NASDAQ:RGNX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Nurix Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

REGENXBIO has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M33.02-$264.46M-$3.45N/A
REGENXBIO$170.44M4.15-$193.88M-$3.79N/A

In the previous week, Nurix Therapeutics had 1 more articles in the media than REGENXBIO. MarketBeat recorded 3 mentions for Nurix Therapeutics and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.36 beat Nurix Therapeutics' score of 0.94 indicating that REGENXBIO is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
REGENXBIO
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.1% of REGENXBIO shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

REGENXBIO has a net margin of -112.58% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics-928.44% -76.09% -57.31%
REGENXBIO -112.58%-220.07%-46.04%

Nurix Therapeutics presently has a consensus target price of $34.21, indicating a potential upside of 28.05%. REGENXBIO has a consensus target price of $23.73, indicating a potential upside of 121.34%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62

Summary

REGENXBIO beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Beam Therapeutics?

REGENXBIO (NASDAQ:RGNX) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Beam Therapeutics had 4 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.36 beat Beam Therapeutics' score of 1.07 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has lower revenue, but higher earnings than REGENXBIO. Beam Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M4.15-$193.88M-$3.79N/A
Beam Therapeutics$139.74M22.00-$79.99M-$0.86N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

REGENXBIO presently has a consensus target price of $23.73, suggesting a potential upside of 121.34%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 64.65%. Given REGENXBIO's higher probable upside, equities analysts clearly believe REGENXBIO is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69

Beam Therapeutics has a net margin of -54.75% compared to REGENXBIO's net margin of -112.58%. Beam Therapeutics' return on equity of -30.71% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-112.58% -220.07% -46.04%
Beam Therapeutics -54.75%-30.71%-24.07%

REGENXBIO has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Summary

Beam Therapeutics beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to SELLAS Life Sciences Group?

REGENXBIO (NASDAQ:RGNX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

SELLAS Life Sciences Group has lower revenue, but higher earnings than REGENXBIO. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M4.15-$193.88M-$3.79N/A
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. SELLAS Life Sciences Group's return on equity of -35.91% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-112.58% -220.07% -46.04%
SELLAS Life Sciences Group N/A -35.91%-33.34%

REGENXBIO presently has a consensus price target of $23.73, indicating a potential upside of 121.34%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential downside of 35.32%. Given REGENXBIO's stronger consensus rating and higher possible upside, research analysts plainly believe REGENXBIO is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

REGENXBIO has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.36 beat SELLAS Life Sciences Group's score of 0.73 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SELLAS Life Sciences Group
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

REGENXBIO beats SELLAS Life Sciences Group on 8 of the 15 factors compared between the two stocks.

How does REGENXBIO compare to Viridian Therapeutics?

REGENXBIO (NASDAQ:RGNX) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

REGENXBIO has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M4.15-$193.88M-$3.79N/A
Viridian Therapeutics$70.85M38.84-$342.60M-$3.37N/A

In the previous week, Viridian Therapeutics had 10 more articles in the media than REGENXBIO. MarketBeat recorded 12 mentions for Viridian Therapeutics and 2 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 1.36 beat Viridian Therapeutics' score of 1.04 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viridian Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

REGENXBIO has a net margin of -112.58% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat REGENXBIO's return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-112.58% -220.07% -46.04%
Viridian Therapeutics -505.86%-72.97%-42.80%

REGENXBIO currently has a consensus price target of $23.73, suggesting a potential upside of 121.34%. Viridian Therapeutics has a consensus price target of $38.93, suggesting a potential upside of 60.27%. Given REGENXBIO's higher possible upside, equities research analysts clearly believe REGENXBIO is more favorable than Viridian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.86

REGENXBIO has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

REGENXBIO beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGNX vs. The Competition

Export
MetricREGENXBIOBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$730.11M$3.96B$7.27B$12.76B
Dividend YieldN/A3.64%2.54%11.08%
P/E Ratio-2.8311.52270.6924.20
Price / Sales4.151,406.67639.59109.22
Price / CashN/A103.2976.8953.23
Price / Book9.8317.9013.436.37
Net Income-$193.88M-$12.50M$3.46B$347.74M
7 Day Performance-0.46%3.23%2.15%0.08%
1 Month Performance5.10%7.72%6.17%2.90%
1 Year Performance18.98%55.10%24.96%17.22%

REGENXBIO Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGNX
REGENXBIO
3.9499 of 5 stars		$10.72
-3.1%		$23.73
+121.3%		+32.2%$730.11M$170.44MN/A370
ZLAB
Zai Lab
2.8031 of 5 stars		$25.81
-0.4%		$40.20
+55.8%		-23.5%$2.94B$449.61MN/A1,784
NRIX
Nurix Therapeutics
2.9139 of 5 stars		$26.89
-0.6%		$34.21
+27.2%		+176.9%$2.79B$83.98MN/A300
BEAM
Beam Therapeutics
2.1501 of 5 stars		$26.95
+0.8%		$49.00
+81.8%		+85.9%$2.78B$139.74MN/A510
SLS
SELLAS Life Sciences Group
0.942 of 5 stars		$13.12
+2.6%		$10.00
-23.8%		+778.4%$2.65BN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel